11 April 2024 1730 BST
Results of Annual General Meeting held on 11 April 2024
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 11 - 14 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
|
| Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Votes cast in total | Total votes cast as a % of issued share capital | Votes withheld |
| 1 | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023 | 1,205,690,871 | 99.88 | 1,470,816 | 0.12 | 1,207,161,687 | 77.87% | 9,700,968 |
| 2 | To confirm dividends | 1,215,177,590 | 99.94 | 790,189 | 0.06 | 1,215,967,779 | 78.44% | 894,978 |
| 3 | To reappoint PricewaterhouseCoopers LLP as Auditor | 1,208,377,872 | 99.36 | 7,843,545 | 0.64 | 1,216,221,417 | 78.45% | 642,048 |
| 4 | To authorise the Directors to agree the remuneration of the Auditor | 1,215,717,786 | 99.98 | 279,816 | 0.02 | 1,215,997,602 | 78.44% | 722,222 |
| 5a | To re-elect Michel Demaré as a Director | 1,197,325,871 | 98.49 | 18,416,788 | 1.51 | 1,215,742,659 | 78.42% | 1,120,559 |
| 5b | To re-elect Pascal Soriot as a Director | 1,206,729,787 | 99.26 | 9,036,742 | 0.74 | 1,215,766,529 | 78.42% | 1,098,706 |
| 5c | To re-elect Aradhana Sarin as a Director | 1,212,225,383 | 99.71 | 3,509,122 | 0.29 | 1,215,734,505 | 78.42% | 1,129,532 |
| 5d | To re-elect Philip Broadley as a Director | 1,197,937,103 | 98.54 | 17,773,671 | 1.46 | 1,215,710,774 | 78.42% | 1,153,360 |
| 5e | To re-elect Euan Ashley as a Director | 1,213,332,278 | 99.80 | 2,375,199 | 0.20 | 1,215,707,477 | 78.42% | 1,156,567 |
| 5f | To re-elect Deborah DiSanzo as a Director | 1,215,396,504 | 99.97 | 318,525 | 0.03 | 1,215,715,029 | 78.42% | 1,149,106 |
| 5g | To re-elect Diana Layfield as a Director | 1,215,424,019 | 99.98 | 292,514 | 0.02 | 1,215,716,533 | 78.42% | 1,147,602 |
| 5h | To elect Anna Manz as a Director | 1,215,297,866 | 99.97 | 417,067 | 0.03 | 1,215,714,933 | 78.42% | 1,149,091 |
| 5i | To re-elect Sheri McCoy as a Director | 1,158,846,767 | 95.32 | 56,874,293 | 4.68 | 1,215,721,060 | 78.42% | 1,142,920 |
| 5j | To re-elect Tony Mok as a Director | 1,215,346,936 | 99.97 | 346,157 | 0.03 | 1,215,693,093 | 78.42% | 1,170,931 |
| 5k | To re-elect Nazneen Rahman as a Director | 1,191,449,316 | 98.59 | 16,988,178 | 1.41 | 1,208,437,494 | 77.95% | 8,426,242 |
| 5l | To re-elect Andreas Rummelt as a Director | 1,215,395,253 | 99.97 | 314,359 | 0.03 | 1,215,709,612 | 78.42% | 1,154,412 |
| 5m | To re-elect Marcus Wallenberg as a Director | 947,479,100 | 77.93 | 268,252,536 | 22.07 | 1,215,731,636 | 78.42% | 1,132,416 |
| 6 | To approve the Annual Report on Remuneration for the year ended 31 December 2023 | 1,158,470,360 | 95.32 | 56,835,406 | 4.68 | 1,215,305,766 | 78.40% | 1,558,941 |
| 7 | To approve the Directors' Remuneration Policy
| 761,702,826 | 64.43 | 420,514,520 | 35.57 | 1,182,217,346 | 76.26% | 34,645,873 |
| 8 | To approve amendments to the AstraZeneca Performance Share Plan 2020
| 769,577,451 | 65.34 | 408,204,003 | 34.66 | 1,177,781,454 | 75.97% | 39,083,170 |
| 9 | To authorise limited political donations | 1,184,223,861 | 98.00 | 24,219,787 | 2.00 | 1,208,443,648 | 77.95% | 8,278,265 |
| 10 | To authorise the Directors to allot shares | 1,129,625,915 | 92.94 | 85,836,406 | 7.06 | 1,215,462,321 | 78.41% | 1,259,562 |
| 11 | To authorise the Directors to disapply pre-emption rights | 1,044,559,011 | 85.95 | 170,708,848 | 14.05 | 1,215,267,859 | 78.39% | 1,454,048 |
| 12 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 997,629,834 | 82.33 | 214,143,713 | 17.67 | 1,211,773,547 | 78.17% | 4,948,031 |
| 13 | To authorise the Company to purchase its own shares | 1,205,828,976 | 99.23 | 9,306,860 | 0.77 | 1,215,135,836 | 78.38% | 1,585,923 |
| 14 | To reduce the notice period for general meetings | 1,131,157,449 | 93.07 | 84,269,754 | 6.93 | 1,215,427,203 | 78.40% | 1,294,801 |
A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Statement in connection with resolutions 5m, 7 and 8
AstraZeneca is pleased that all resolutions were supported at today's Annual General Meeting. In particular, the Board thanks the majority of our shareholders who have supported the Remuneration Policy (the Policy) and will continue to engage with our shareholders and the proxy advisors to explain our need for global benchmarks and pay for performance, which is driven by the Policy.
We will publish an update on the engagement with shareholders on resolutions 5m, 7 and 8 and on any action taken as a result within six months of today's AGM, in accordance with the UK Corporate Governance Code.
Issued capital
As at 9 April 2024, the number of issued shares of the Company was 1,550,231,084 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.